Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies

被引:21
作者
Pisal, Mahesh M. [1 ]
Nawale, Laxman U. [2 ]
Patil, Manoj D. [1 ]
Bhansali, Sujit G. [2 ]
Gajbhiye, Jayant M. [1 ]
Sarkar, Dhiman [2 ]
Chavan, Subhash P. [1 ]
Borate, Hanumant B. [1 ]
机构
[1] CSIR Natl Chem Lab, Div Organ Chem, Dr Homi Bhabha Rd, Pune 411008, Maharashtra, India
[2] CSIR Natl Chem Lab, Combichem Bioresource Ctr, Dr Homi Bhabha Rd, Pune 411008, Maharashtra, India
关键词
Tuberculosis; Antitubercular activity; Thienopyrimidinone; Thiouracil; Docking; MYCOBACTERIUM-TUBERCULOSIS; ACCURATE DOCKING; BOVIS BCG; INHIBITORS; IDENTIFICATION; DESIGN; DORMANT; POTENT; GLIDE;
D O I
10.1016/j.ejmech.2017.01.009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A number of hybrid molecules containing thienopyrimidinones and thiouracil moieties were designed, synthesized and tested against Mycobacterium tuberculosis H37Ra wherein it was observed that the compounds 11-14 exhibited antitubercular activity in vitro (MIC 7.6-19.1 mu g/mL, 12-35 mu M) against dormant stage while the compound 15 exhibited antitubercular activity in vitro against dormant (MIC 23.4 mu g/mL, 41 mu M) as well as active (MIC 25.4 mu g/mL, 45 mu M) stage. Structural modifications of the compound 15 were carried out to study the structure-activity relationship and it was observed that the compound 18 exhibited antitubercular activity comparable to the compound 15. Cytotoxicity studies revealed that these molecules were non-toxic. The docking study of the compound 15 showed that there was binding with the active site of mycobacterial pantothenate synthetase. Further docking studies led to the synthesis of the compounds 16 and 17 and the antitubercular activity screening results showed that these compounds have significant antitubercular activity. The compounds 15-18 (MIC 11-29 mu g/mL, 19 51 mu M) can be used as starting points for further optimization. The synthetic strategies used in the present work have potential to prepare a large number of compounds for further refinement of structures and the present results will be very useful in the development of a new class of antimycobacterial agents. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:459 / 469
页数:11
相关论文
共 51 条
[1]   Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening [J].
Abrahams, Garth L. ;
Kumar, Anuradha ;
Savvi, Suzana ;
Hung, Alvin W. ;
Wen, Shijun ;
Abell, Chris ;
Barry, Clifton E., III ;
Sherman, David R. ;
Boshoff, Helena I. M. ;
Mizrahi, Valerie .
CHEMISTRY & BIOLOGY, 2012, 19 (07) :844-854
[2]  
[Anonymous], 2015, Global Tuberculosis Report
[3]  
[Anonymous], 2016, Glide, Version 7.1
[4]  
[Anonymous], PRIM VERS 4 4
[5]   Specialized transduction:: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M-bovis BCG and M-smegmatis [J].
Bardarov, S ;
Bardarov, S ;
Pavelka, MS ;
Sambandamurthy, V ;
Larsen, M ;
Tufariello, J ;
Chan, J ;
Hatfull, G ;
Jacobs, WR .
MICROBIOLOGY-SGM, 2002, 148 :3007-3017
[6]   Novel pyrimidine and its triazole fused derivatives: Synthesis and investigation of antioxidant and anti-inflammatory activity [J].
Bhalgat, Chetan M. ;
Ali, M. Irfan ;
Ramesh, B. ;
Ramu, G. .
ARABIAN JOURNAL OF CHEMISTRY, 2014, 7 (06) :986-993
[7]  
Borate H. B., 2015, PCT Appl., Patent No. [PCT/IN2015/000054, 2015000054]
[8]  
Borate H. B., 2015, [No title captured], Patent No. [WO 2015114663 A1, 2015114663]
[9]  
Borate H. B., 2009, [No title captured], Patent No. [WO 2009/109983 A1, 2009109983]
[10]  
Borate H. B., 2012, European pat, Patent No. [EP 2257555 B1, 2257555]